Skip to content
Immune Biosolutions
  • Technologies
  • About Us
  • ServicesExpand
    • Partnerships
    • Resources available
  • NEWS
  • Contact us
Pipeline
  • Fr
Immune Biosolutions

NEWS

New Research Collaboration with Janssen Biotech

6 August 201831 March 2023

Immune Biosolutions Enters into a Research Collaboration and License Agreement with Johnson & Johnson Innovation to Identify and Develop Therapeutic…

Read More New Research Collaboration with Janssen BiotechContinue

Immune Biosolutions Participating in Futurpreneur’s Growth Accelerator

26 June 201831 March 2023

After winning a pitch competition earlier this year, Immune Biosolutions’ founders are participating this week in the Futurpreneur’s Growth Accelerator…

Read More Immune Biosolutions Participating in Futurpreneur’s Growth AcceleratorContinue

CQDM to support a $1.1 million Immune Biosolutions’ research project.

12 June 20183 April 2023

CQDM to support a $1.1 million research and development project for Immune Biosolutions’ next-generation of anti-cancer treatment BOSTON, JUNE 6,…

Read More CQDM to support a $1.1 million Immune Biosolutions’ research project.Continue

Immune Biosolutions to Present at ICCS 2018

23 May 201828 March 2023

Immune Biosolutions has been selected to present at the 7th International Cancer Cluster Showcase 2018 in Boston during the BIO Convention…

Read More Immune Biosolutions to Present at ICCS 2018Continue

Immune Biosolutions delegates to participate to BIO Convention 2018 in Boston

18 May 2018

Immune Biosolutions’ team will once again participate to one of the largest life sciences convention in North America. Frédéric Leduc,…

Read More Immune Biosolutions delegates to participate to BIO Convention 2018 in BostonContinue

Immune Biosolutions to participate to Knowledge for Growth 2018 in Belgium

10 May 2018

Chief Executive Officer, Frédéric Leduc, and Chief Scientific Officer, Simon Gaudreau, will be representing Immune Biosolutions next week at the 14th…

Read More Immune Biosolutions to participate to Knowledge for Growth 2018 in BelgiumContinue

Immune Biosolutions to Present at Bio€quity Europe 2018

2 May 2018

Immune Biosolutions, a Canadian biotech company specialized in the discovery and engineering of humanized chicken antibodies, will present its proprietary Nebula Discovery platform…

Read More Immune Biosolutions to Present at Bio€quity Europe 2018Continue

Immune Biosolutions selected for JLABS @ Toronto

1 April 201728 March 2023

Immune Biosolutions selected for JLABS @ Toronto Immune Biosolutions is among the 22 growing businesses selected for JLABS @ Toronto….

Read More Immune Biosolutions selected for JLABS @ TorontoContinue

Immune Biosolutions will continue its growth at EspaceLabz

1 March 201728 March 2023

Immune Biosolutions, a JLABS @ Toronto resident, is pleased to announce the relocation of its Sherbrooke headquarters and laboratories in…

Read More Immune Biosolutions will continue its growth at EspaceLabzContinue

G Protein-Coupled Receptors targeted by antibodies raised against three dimensional epitopes

1 January 2017

Why target GPCRs with antibodies? The G Protein-coupled receptor (GPCR) superfamily represents the largest and single most important family of…

Read More G Protein-Coupled Receptors targeted by antibodies raised against three dimensional epitopesContinue

Page navigation

Previous PagePrevious 1 2

Search

Search

Search

CONTACT US

819 564-5283 [email protected]

ADDRESS

Immune Biosolutions Inc.
2-2650, rue Maximilien-Chagnon
Sherbrooke, QC J1E 0M8
Canada

© 2025 Immune Biosolutions | Privacy policy | Cookies Preferences

Created with passion by

Conceptions Web Standish Communications

  • Technologies
  • About Us
  • Services
    • Partnerships
    • Resources available
  • NEWS
  • Contact us

Pipeline

  • Fr